COMPARISON GRID / EVIDENCE BEFORE ENTHUSIASM
Do Not Compare Promises. Compare Questions.
Four compounds share a conversation, not a mechanism: the useful comparison is evidence maturity, studied outcome, route, and clinical context.
In plain English: these are not alternatives to one another
Semaglutide, GHK-Cu, NAD+, and PT-141 sometimes appear together under the broad language of peptide health. They should not be lined up like four versions of the same tool. Semaglutide is an approved GLP-1 medicine with large trials. GHK-Cu is a copper-binding tripeptide with mostly topical and preclinical evidence. NAD+ is a coenzyme—not a peptide—and human research often studies its precursors. PT-141, or bremelanotide, is a centrally acting prescription peptide approved for a narrow sexual-desire condition in a defined population [13][22].
The shared task is better questioning. What is the actual health goal? Is the evidence a cell experiment, a biomarker trial, a small topical study, or a large clinical outcome trial? Was the product a regulated medicine, a cosmetic ingredient, a precursor supplement, or something unverified? Which safety issues matter before efficacy is discussed? Seen this way, comparison does not crown a winner. It reveals which evidence belongs to which conversation—and which conclusions cannot responsibly cross the boundary.
The evidence map
| Dossier | Biological lane | Strongest evidence represented here | Studied health question | Central caution |
|---|---|---|---|---|
| Semaglutide | GLP-1 receptor signaling in pancreas, gut, brain, and other organs | Large randomized human outcome trials [2][3][4] | Weight, cardiovascular events, and kidney outcomes in defined populations | Gastrointestinal effects, biliary disease, retinopathy context, and other prescription-drug cautions [5][7] |
| GHK-Cu | Copper carriage, matrix remodeling, and repair signaling | Reviews, small topical studies, a combination hair trial, and ex vivo skin delivery [8][10][11][12] | Skin appearance, formulation delivery, and hair-related signals | Human evidence is small and route-sensitive; systemic use is not an approved extension |
| NAD+ | Cellular redox chemistry and enzyme substrate | Human oral-precursor trials plus major reviews [13][14][15][17] | Whether NMN or NR raises NAD+ and changes selected functional or metabolic measures | A blood biomarker is not a clinical endpoint; products and routes are not interchangeable |
| PT-141 | Central MC4R/MC3R melanocortin signaling | Phase 3 trials, neuroimaging, long-term extension, and regulatory label [19][20][21][22] | Desire and distress in premenopausal women with acquired, generalized HSDD | Narrow indication, nausea, transient blood-pressure rise, and pigment changes |
Mechanism answers ‘how’; it does not answer ‘for whom’
Semaglutide activates one named receptor class, yet its clinical meaning spans appetite, glucose, heart, and kidney outcomes because those questions were tested in large trials [2][3][4]. GHK-Cu’s mechanism is more diffuse: matrix components, remodeling enzymes, antioxidant systems, and expression patterns appear in its research story [9][11]. The breadth is intellectually interesting but does not substitute for large human trials.
NAD+ is broader still because it is basic cellular currency. Its necessity can tempt a false inference: if cells need it, more must make a person healthier. Human precursor studies support movement in the biomarker, while a contemporary review finds downstream efficacy inconsistent [13][14][17]. PT-141 offers the reverse shape—a narrower receptor story and a narrow studied indication [19][20].
Mechanism helps a clinician ask whether an observed effect is plausible, anticipate related adverse effects, and connect an endpoint to physiology. Population, comparator, duration, diagnosis, and regulation answer the other half.
Evidence maturity changes the grammar
For semaglutide, the literature permits sentences about randomized outcome differences in many thousands of participants [2][3][4]. For GHK-Cu, careful language stays closer to “associated with,” “reported in a small topical study,” or “observed ex vivo” [8][10][12]. For NAD+, the verb often belongs to a precursor: NMN or NR raised blood NAD+, while broader clinical benefit remains unsettled [13][14][17]. For PT-141, every efficacy sentence should keep the HSDD population attached [20].
This difference in grammar is not hedging for its own sake. It prevents a preclinical mechanism from dressing up as a clinical outcome and prevents a narrow approval from sounding universal. It also produces better clinician questions: What outcome was actually tested? Was it objective, subjective, biochemical, or event-based? Did the study include a placebo or comparator? Is there evidence for the proposed route? How closely does the studied population resemble the patient?
A health-goal conversation worksheet
A reader can bring four columns to a licensed clinician: goal, evidence, personal context, and next question. Under goal, name the outcome without naming a compound—such as appetite regulation, skin appearance, fatigue, or low sexual desire. Under evidence, identify the best human study and whether it measured the same thing. Under context, note relevant diagnoses, medicines, symptoms, prior care, and regulatory product status. Under next question, ask what would clarify the cause or change the decision.
For metabolism, outcome trials and prescription safety lead. For skin, diagnosis, topical formulation, irritation, and the limits of small studies lead. For fatigue or aging claims, a clinician may first ask what else explains the symptom and whether the proposed endpoint goes beyond a blood marker. For sexual concerns, diagnosis and cardiovascular context precede a molecule.
That process preserves curiosity without letting curiosity impersonate care. The individual dossiers offer depth; the FAQ addresses common starting questions; the references keep the original papers close.